Acumen Pharmaceuticals | Evaluate

AAIC 2023 – Acumen’s new amyloid approach impresses

But how different is ACU193 really?

September 29, 2022

The Alzheimer's stocks riding on lecanemab's coat tails

June 10, 2021

The next wave of amyloid-targeting projects approaches

Acumen is the latest player to take aim at amyloid, but competition is fierce.